{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:34:33Z","timestamp":1790890473564,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Oritavancin is a lipoglycopeptide antibacterial agent used to treat infections caused by Gram-positive organisms. It is FDA-approved for the treatment of acute bacterial skin and soft tissue infections (ABSSIs) but is increasingly being used off-label to treat invasive bacterial infections such as osteomyelitis, prosthetic joint infection and infective endocarditis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study describes the clinical outcomes and adverse reactions related to oritavancin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>This was a retrospective study conducted over a 5 year period at a tertiary care medical centre. Ninety-five adult patients were included in this study and were followed for 1 year after the last dose of oritavancin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The most common indication for oritavancin at our institution was osteomyelitis, followed by ABSSI. Other indications were vertebral infection, hardware-associated infection, bacteraemia and infective endocarditis. Fourteen percent (13\/95) of patients developed an adverse reaction to oritavancin during the study period. Cure with no recurrence up to 1 year after the last dose of oritavancin was achieved in 74% (53\/71) of patients, and the treatment failure rate was 19% (14\/71 patients).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Oritavancin is an effective agent that can be used to treat invasive Gram-positive bacterial infections other than ABSSI. Adverse events requiring drug discontinuation were common.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlae174","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T04:38:35Z","timestamp":1730349515000},"source":"Crossref","is-referenced-by-count":8,"title":["Experience with expanded use of oritavancin in a tertiary hospital: indications, tolerability and outcomes"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-0096","authenticated-orcid":false,"given":"Thilinie Dulanjalee","family":"Bandaranayake","sequence":"first","affiliation":[{"name":"Section of Infectious Diseases, Yale School of Medicine , TAC S 169, PO BOX 208022, New Haven, CT 06520 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Radcliffe","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Yale School of Medicine , TAC S 169, PO BOX 208022, New Haven, CT 06520 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Cvercko","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ambulatory Clinical Pharmacy Specialist II, Yale New Haven Hospital , 55 Park Street, New Haven, CT 06511 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6129-9216","authenticated-orcid":false,"given":"Marjorie","family":"Golden","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Yale School of Medicine , TAC S 169, PO BOX 208022, New Haven, CT 06520 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritche Manos","family":"Hao","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Yale School of Medicine , TAC S 169, PO BOX 208022, New Haven, CT 06520 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"2024122015545991300_dlae174-B1","doi-asserted-by":"publisher","first-page":"dlaa114","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"3","author":"Brown","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2024122015545991300_dlae174-B2","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/jac\/dkp126","article-title":"Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium","volume":"63","author":"McKay","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2024122015545991300_dlae174-B3","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"2024122015545991300_dlae174-B4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s40801-020-00194-8","article-title":"Real-world use of oritavancin for the treatment of osteomyelitis","volume":"7","author":"Scoble","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"2024122015545991300_dlae174-B5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3390\/life13040959","article-title":"Role of oritavancin in the treatment of infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans. Narrative review and possible developments","volume":"13","author":"Lupia","year":"2023","journal-title":"Life (Basel)"},{"key":"2024122015545991300_dlae174-B6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/cid\/civ311","article-title":"Oritavancin: a long-half-life lipoglycopeptide","volume":"61","author":"Saravolatz","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024122015545991300_dlae174-B7","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.3390\/antibiotics12101498","article-title":"The clinical efficacy of multidose oritavancin: a systematic review","volume":"12","author":"Baiardi","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2024122015545991300_dlae174-B8","doi-asserted-by":"publisher","first-page":"ofz479","DOI":"10.1093\/ofid\/ofz479","article-title":"The CHROME study, a real-world experience of single- and multiple-dose oritavancin for treatment of gram-positive infections","volume":"6","author":"Redell","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024122015545991300_dlae174-B9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/pharmacy8020070","article-title":"Glycopeptide hypersensitivity and adverse reactions","volume":"8","author":"Huang","year":"2020","journal-title":"Pharmacy (Basel)"},{"key":"2024122015545991300_dlae174-B10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40801-020-00195-7","article-title":"Treatment of acute osteomyelitis with once-weekly oritavancin: a two-year, multicenter, retrospective study","volume":"7","author":"Van Hise","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"2024122015545991300_dlae174-B11","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024122015545991300_dlae174-B12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s40801-020-00188-6","article-title":"A two-dose oritavancin regimen using pharmacokinetic estimation analysis","volume":"7","author":"Rose","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"2024122015545991300_dlae174-B13","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1128\/AAC.03029-15","article-title":"Results from oritavancin resistance surveillance programs (2011 to 2014): clarification for using vancomycin as a surrogate to infer oritavancin susceptibility","volume":"60","author":"Jones","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/6\/dlae174\/61219926\/dlae174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/6\/dlae174\/61219926\/dlae174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T15:55:07Z","timestamp":1734710107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlae174\/7852930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlae174","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,30]]},"article-number":"dlae174"}}